The 2010 Investment U Conference is underway! And even if you couldn't make it, now you can "bring home" more than 30 breakthrough presentations from the conference... Order the Deluxe MP3/Video Library for $99 to listen and view on your computer, or the Premier CD plus MP3/Video Library for $149 to listen to and view anywhere.
The Healthcare Debate: We’ll Stick to Earning Profits
by Robert Williams, Publisher
Wednesday, October 28, 2009
Pop quiz: Name the industry that has racked up the second-best stock performance over the past 100 years. (Tobacco stocks are No.1.)
I’ll give you a hint. It’s about as recession-proof as you can get. It’s critical to every American. And it’s future is the mostly hotly debated topic this side of Wall Street.
The answer, of course, is healthcare.
Pundits can debate the issues all they want. In the meantime, we’ll continue to breakdown the sector for its investment appeal.
Recall, last week Louis Basenese said that healthcare M&A action is at an all-time high, as companies jostle to position themselves for whatever reform comes out of Washington.
For example, GlaxoSmithKline (NYSE: GSK) just shelled out $680 million for a worldwide partnership with Dutch biopharma firm ProSensa for its therapeutics drugs. And Onyx Pharmaceuticals (Nasdaq: ONXX) paid $851 million ($276 million upfront) for Proteolix.
More deals are no doubt forthcoming. Fortunately, our healthcare and biotechnology expert Marc Lichtenfeld is here to guide us through his powerful, five-step system, which meticulously pinpoints the best stocks to buy.
(And pssst! Marc told me that a slew of healthcare stocks are trading at bargain-basement levels. So this could be one of the best times to buy.)
Ahead of the tape,
Robert Williams
- Healthcare M&A Activity: Three Healthcare Small Caps Primed For Takeovers
- Look Who Just Showed Up to the Takeover Party
- Biotech Stocks: The Market’s Best Bargain Right Now…
|
The Company Set to Dominate a $60 Billion-a-Year Market
$60 billion is spent on cancer treatment in the U.S. - each year. And one company is poised to receive the lion's share of it.
The medical director at the Alta Bates Comprehensive Cancer Center says, "...possibly a third of our cancer patient population will soon be undergoing this [company's] treatment."
Another doctor at the University of Texas MD Anderson Cancer Center says he intends to treat over 1,000 patients a year with this technology.
Here's how you can claim your stake in the company before this cash infusion sends shares soaring.
Comments
**By submitting your comment you agree to adhere to our Comment Policy and Privacy Policy.Check out our selection of daily Investment Research:
 |
 |
In addition to once being a full-time trader of equities and equity derivatives, Robert Williams has served as the lead financial analyst for a Forbes top-50 private corporation and an analyst for the endowment of a major academic institution. He's also been profiled in such books as Trade with Passion and Purpose and Alexander Green's The Secret of Shelter Island. 
Investment U RSS Feed